SOX5 and type 2 diabetes mellitus: Overexpression of SOX5 in non-diabetic islets increased glucose-stimulated insulin secretion by 0.23 percentage points (of insulin content), while secretion was improved by 0.68 percentage points in T2D islets (P=0.04), partly restoring the impaired insulin release.